Radiation Therapy With Capecitabine in Rectal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00176787|
Recruitment Status : Terminated (recruitment goals met)
First Posted : September 15, 2005
Last Update Posted : January 10, 2008
This study will use an experimental combination of treatment with the drug Capecitabine and radiation therapy prior to an operation for removal of the patient's tumor. The drug Capecitabine is an oral form of a drug called 5-FU which has been widely used to treat rectal cancer.
This is a phase II clinical trial, which means that the physician will be studying the reactions of the patient's body and tumor to treatment with Capecitabine and radiation therapy. The purpose of this study is to see if the tumor responds to this treatment and to determine how long the response lasts. The study also will see what kind of side effects this experimental treatment causes and see how often these side effects occur.
Preliminary human studies using Capecitabine and radiation therapy have produced encouraging results with acceptable side effects.
|Condition or disease||Intervention/treatment||Phase|
|Rectal Cancer||Drug: Capecitabine Procedure: Radiation Procedure: Surgery||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial of Preoperative Radiation Therapy With Capecitabine in Rectal Cancer (UMCC 0046)|
|Study Start Date :||October 2000|
|Primary Completion Date :||May 2005|
|Study Completion Date :||June 2007|
- In patients with locally advanced rectal cancer treated with preoperative radiation and capecitabine chemotherapy to estimate:
- a. the pathologic complete response rate
- b. the clinical response rate
- c. the proportion of patients converted to sphincter sparing surgery
- clinical response rate [ Time Frame: 2 cycles ]
- d. The quantitative and qualitative toxicities of the treatment approach
- e. The relationship of intratumoral levels of thymidylate synthase, dipyrimidine dehydrogenase and thymidine phosphorylase determined immunohistochemically to response
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00176787
|United States, Michigan|
|University of Michigan Cancer Center|
|Ann Arbor, Michigan, United States, 48109|
|Principal Investigator:||Mark Zalupski, M.D.||University of Michigan Cancer Center|